How Clinical Pathways Can be Used For HER2-Positive Breast Cancer Therapies

 In a presentation at the 2023 Clinical Pathways Congress with the Cancer Care Business Exchange (CPC & CBEx 2023), Sayeh Lavasani, MD, MS, FRCPC, from the UC Irvine Cancer Center, discussed the numerous approaches providers can take to address different needs through clinical pathways for HER2-positive (HER2+) breast cancer care.

Access the full article to read more here.